Synapse

← Mathew S. Maurer

Papers by Mathew S. Maurer

Page 2 · newest first

  1. Risk for Heart Failure and Atrial Fibrillation Across the Lifespan for Carriers of the Amyloidogenic p.V142I TTR VariantCirculation Genomic and Precision Medicine · 2025
  2. Detecting structural heart disease from electrocardiograms using AINature · 2025
  3. Prognostic Value of Malnutrition, Frailty, and Physical Performance in Transthyretin Cardiac Amyloidosis: Insights From a Prospective Multicenter Cohort StudyCirculation Heart Failure · 2025
  4. Cardiac amyloidosis detection from a single echocardiographic video clip: a novel artificial intelligence-based screening toolEuropean Heart Journal · 2025
  5. Cardiac Amyloidosis in Older Adults With a Focus on FrailtySHILAP Revista de lepidopterología · 2025
  6. Early Increase in Serum Transthyretin by Acoramidis Independently Predicts Improved Survival in TTR Amyloid CardiomyopathyJournal of the American College of Cardiology · 2025
  7. Acoramidis for Transthyretin Amyloid Cardiomyopathy: Open-Label Extension Study Long-Term Follow-UpJournal of Cardiac Failure · 2025
  8. Cardiac disease monitoring measures in patients with transthyretin amyloid cardiomyopathy treated with tafamidisHeart · 2025
  9. Efficacy of Acoramidis on All-Cause Mortality and Cardiovascular Hospitalization in Transthyretin Amyloid CardiomyopathyJournal of the American College of Cardiology · 2025
  10. Guideline-Directed Medical Therapy for Heart Failure in Transthyretin Amyloid CardiomyopathyCirculation Heart Failure · 2025
  11. A Multicenter Study of Contemporary Long-Term Tafamidis Outcomes in Transthyretin Amyloid CardiomyopathyJACC CardioOncology · 2025
  12. Previous surgery for lumbar spinal stenosis and association with amyloidosis and heart failure – A Danish nationwide studyAmyloid · 2025
  13. Plasma SVEP1 Levels Predict Cardiovascular Events in Hypertrophic Cardiomyopathy Beyond Conventional Clinical Risk Models Including NT-proBNPCirculation Heart Failure · 2025
  14. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicineEuropean Heart Journal · 2025
  15. Diagnostic pathways, cardiac manifestations and outcomes in light chain amyloidosis: analysis of a US claims databaseOpen Heart · 2025
  16. Outpatient Worsening of Heart Failure and Mortality in Transthyretin Amyloid CardiomyopathyEuropean Journal of Heart Failure · 2024
  17. Estimating Meaningful Differences in Measures of Neuropathic Impairment, Health‐Related Quality of Life, and Nutritional Status in Patients With Hereditary Transthyretin AmyloidosisMuscle & Nerve · 2024
  18. Chest pain and coronary artery disease in cardiac amyloidosis: Prevalence, mechanisms, and clinical implicationsAmerican Heart Journal · 2024
  19. Comprehensive Proteomics Profiling Identifies Circulating Biomarkers to Distinguish Hypertrophic Cardiomyopathy From Other Cardiomyopathies With Left Ventricular HypertrophyCirculation Heart Failure · 2024
  20. Prediction of new-onset atrial fibrillation in patients with hypertrophic cardiomyopathy using plasma proteomics profilingEP Europace · 2024
  21. Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baselineEuropean Heart Journal · 2024
  22. Improved Access to Genetics Care is Needed to Address Health Inequities in ATTRv AmyloidosisCirculation · 2024
  23. Vutrisiran in Patients with Transthyretin Amyloidosis with CardiomyopathyNew England Journal of Medicine · 2024
  24. Monitoring for arrhythmia in transthyretin cardiac amyloidosis with noninvasive ambulatory patch devicesHeart Rhythm O2 · 2024
  25. Comprehensive Geriatric Assessment to Optimize the Management of Older Patients With Transthyretin Cardiac AmyloidosisJACC Advances · 2024
  26. Age- and Sex-Related Differences in Patients With Wild-Type Transthyretin AmyloidosisJACC Advances · 2024
  27. Deep Learning for Echo Analysis, Tracking, and Evaluation of Mitral Regurgitation (DELINEATE-MR)Circulation · 2024
  28. Survival in a Real-World Cohort of Patients With Transthyretin Amyloid Cardiomyopathy Treated With Tafamidis: An Analysis From the Transthyretin Amyloidosis Outcomes Survey (THAOS)Journal of Cardiac Failure · 2024
  29. Addressing Health Disparities—The Case for Variant Transthyretin Cardiac Amyloidosis Grows StrongerJAMA · 2024
  30. Treatment of transthyretin cardiac amyloidosisCurrent Opinion in Cardiology · 2024
  31. Abstract P159: Echocardiographic Cardiac Phenotype in Val122Ile Variant Transthyretin Amyloidosis Among Hispanics/Latinos: Results From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)Circulation · 2024
  32. Abstract P158: Prevalence of Val122Ile Variant Transthyretin Amyloidosis Mutation Among Hispanics/Latinos: Insights From the Hispanic Community Health Study/ Study of Latinos (HCHS/SOL)Circulation · 2024
  33. Sodium–Glucose Cotransporter 2 Inhibitors for Transthyretin Amyloid Cardiomyopathy: Analyses of Short-Term Efficacy and SafetyEuropean Journal of Heart Failure · 2024
  34. Gait abnormalities in older adults with transthyretin cardiac amyloidosisAmyloid · 2024
  35. Impact of Vutrisiran on Exploratory Cardiac Parameters in Hereditary Transthyretin-Mediated Amyloidosis with PolyneuropathyEuropean Journal of Heart Failure · 2024
  36. Moving towards establishing centres of excellence in cardiac amyloidosis: an International Cardio-Oncology Society statementHeart · 2024
  37. Limitations of apical sparing pattern in cardiac amyloidosis: a multicentre echocardiographic studyEuropean Heart Journal - Cardiovascular Imaging · 2024
  38. Efficacy and Safety of Acoramidis in Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine · 2024
  39. Clinical and Genotype Characteristics and Symptom Migration in Patients With Mixed Phenotype Transthyretin Amyloidosis from the Transthyretin Amyloidosis Outcomes SurveyCardiology and Therapy · 2023
  40. Safety and efficacy of teclistamab in systemic immunoglobulin light chain amyloidosisBlood Cancer Journal · 2023
  41. Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid CardiomyopathyJAMA Cardiology · 2023
  42. A 15-year consolidated overview of data in over 6000 patients from the Transthyretin Amyloidosis Outcomes Survey (THAOS)Orphanet Journal of Rare Diseases · 2023
  43. Abstract 14362: The Columbia Score Predicts Incident Atrial Fibrillation and Flutter in Patients With Transthyretin Cardiac AmyloidosisCirculation · 2023
  44. Patisiran Treatment in Patients with Transthyretin Cardiac AmyloidosisNew England Journal of Medicine · 2023
  45. Clonal Hematopoiesis in Clinical and Experimental Heart Failure With Preserved Ejection FractionCirculation · 2023
  46. Patients with transthyretin amyloidosis enrolled in THAOS between 2018 and 2021 continue to experience substantial diagnostic delayAmyloid · 2023
  47. Association of Modified Body Mass Index With In-Hospital Outcomes After Intermediate or High-Risk Pulmonary EmbolismJournal of the Society for Cardiovascular Angiography & Interventions · 2023
  48. Design and Rationale the SCAN‐MP (Screening for Cardiac Amyloidosis With Nuclear Imaging in Minority Populations) StudyJournal of the American Heart Association · 2023
  49. Clinical and social determinants of health features of SARS-CoV-2 infection among Black and Caribbean Hispanic patients with heart failure: The SCAN-MP StudyPLoS ONE · 2023
  50. Association of Tafamidis With Health Status in Patients With ATTR Cardiac AmyloidosisJAMA Cardiology · 2023